Market Overview

Milberg LLP Announces Pendency of Class Action Lawsuits Filed Against Peregrine Pharmaceuticals

Related PPHM
New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab's Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors in Breast Cancer and Melanoma
New Translational Data Highlights Bavituximab's Ability to Induce Signs of Immune Activation in Lung Cancer Tumor Samples With Negative PD-L1 Expression

Milberg LLP announces that class action lawsuits were filed in the United States District Court for the Central District of California on behalf of purchasers of Peregrine Pharmaceuticals, Inc. (“Peregrine”) (NASDAQ: PPHM) common stock during the period July 16, 2012 to September 26, 2012, (the “Class Period”).

Milberg LLP has created a website ( that seeks to answer common questions about shareholder class actions.

Posted-In: News FDA


Related Articles (PPHM)

View Comments and Join the Discussion!

Get Benzinga's Newsletters